Theravance Biopharma, Inc. (TBPH)

Theravance Biopharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Nov 26, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	1,011	463	560	755	814	1,137
Market Cap Growth	127.70%	-17.33%	-25.82%	-7.35%	-28.37%	-22.63%
Enterprise Value	723	416	477	320	1,269	1,398
Last Close Price	19.96	9.41	11.24	11.22	11.05	17.77
PE Ratio	34.40	-	-	0.87	-	-
PS Ratio	12.41	7.19	9.75	14.70	14.72	15.82
PB Ratio	4.35	2.64	2.63	1.71	-2.40	-3.74
P/TBV Ratio	4.35	2.64	2.63	1.71	-	-
EV/Sales Ratio	9.00	6.47	8.30	6.23	22.95	19.46
Debt / Equity Ratio	0.19	0.28	0.23	0.12	-1.98	-2.23
Asset Turnover	0.21	0.18	0.12	0.11	0.13	0.16
Quick Ratio	9.30	4.89	4.84	11.99	3.20	2.93
Current Ratio	9.48	5.02	5.39	12.31	4.26	3.18
Return on Equity (ROE)	14.03%	-29.04%	-16.86%	-179.84%	-	-
Return on Assets (ROA)	-5.32%	-7.21%	-6.78%	-10.07%	-35.20%	-42.38%
Return on Capital (ROIC)	-8.08%	-10.88%	-8.87%	-11.99%	-42.23%	-56.44%
Return on Capital Employed (ROCE)	-8.70%	-13.20%	-15.00%	-13.70%	-75.10%	-86.10%
Earnings Yield	2.90%	-12.19%	-9.86%	115.58%	-24.49%	-24.45%
FCF Yield	24.07%	-2.56%	-5.27%	-24.86%	-25.94%	-22.61%
Buyback Yield / Dilution	-3.49%	11.67%	24.85%	-5.95%	-11.41%	-12.11%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q